Phase III Efficacy Still Unproven, Pimavanserin Bags Acadia Deal With Biovail
This article was originally published in The Pink Sheet Daily
Executive Summary
First of two Phase III studies in Parkinson’s disease psychosis is set to yield data in the third quarter.
You may also be interested in...
Acadia Now Has The Cash To Finish Phase III On Its Own
After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.
Biovail Presses Forward With CNS Agenda
Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.
Biovail Presses Forward With CNS Agenda
Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.